Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for BioCorRx (BICX) over the last 12 years, with Q3 2025 value amounting to $868743.0.

  • BioCorRx's Change in Accured Expenses rose 11475.15% to $868743.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 962.07%. This contributed to the annual value of $1.4 million for FY2024, which is 7957.03% up from last year.
  • BioCorRx's Change in Accured Expenses amounted to $868743.0 in Q3 2025, which was up 11475.15% from $934022.0 recorded in Q2 2025.
  • Over the past 5 years, BioCorRx's Change in Accured Expenses peaked at $934022.0 during Q2 2025, and registered a low of -$402386.0 during Q2 2021.
  • In the last 5 years, BioCorRx's Change in Accured Expenses had a median value of $262444.0 in 2022 and averaged $294793.5.
  • As far as peak fluctuations go, BioCorRx's Change in Accured Expenses surged by 52758.03% in 2023, and later crashed by 10296.97% in 2024.
  • Quarter analysis of 5 years shows BioCorRx's Change in Accured Expenses stood at $307991.0 in 2021, then crashed by 46.83% to $163767.0 in 2022, then increased by 25.55% to $205612.0 in 2023, then plummeted by 102.97% to -$6106.0 in 2024, then surged by 14327.69% to $868743.0 in 2025.
  • Its Change in Accured Expenses stands at $868743.0 for Q3 2025, versus $934022.0 for Q2 2025 and $16333.0 for Q1 2025.